{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:08:46Z","timestamp":1792782526687,"version":"4.5.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2022,12,27]],"date-time":"2022-12-27T00:00:00Z","timestamp":1672099200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,12,27]],"date-time":"2022-12-27T00:00:00Z","timestamp":1672099200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["EXC 2145 SyNergy \u2013 ID 390857198"],"award-info":[{"award-number":["EXC 2145 SyNergy \u2013 ID 390857198"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Universit\u00e4tsklinik M\u00fcnchen"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2023,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>\n                      Characteristic features of amyloid-PET (A), tau-PET (T), and FDG-PET (N) can serve for the A\/T\/N classification of neurodegenerative diseases. Recent studies showed that the early, perfusion-weighted phases of amyloid- or tau-PET recordings serve to detect cerebrometabolic deficits equally to FDG-PET, therefore providing a surrogate of neuronal injury. As such, two channels of diagnostic information can be obtained in the setting of a single PET scan. However, there has hitherto been no comparison of early-phase amyloid- and tau-PET as surrogates for deficits in perfusion\/metabolism. Therefore, we undertook to compare [\n                      <jats:sup>18<\/jats:sup>\n                      F]flutemetamol-amyloid-PET and [\n                      <jats:sup>18<\/jats:sup>\n                      F]PI-2620 tau-PET as \u201cone-stop shop\u201d dual purpose tracers for the detection of neurodegenerative disease.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We obtained early-phase PET recordings with [\n                      <jats:sup>18<\/jats:sup>\n                      F]PI-2620 (0.5\u20132.5\u00a0min p.i.) and [\n                      <jats:sup>18<\/jats:sup>\n                      F]flutemetamol (0\u201310\u00a0min p.i.) in 64 patients with suspected neurodegenerative disease. We contrasted global mean normalized images (SUVr) in the patients with a normal cohort of 15 volunteers without evidence of increased pathology to \u03b2-amyloid- and tau-PET examinations. Regional group differences of tracer uptake (z-scores) of 246 Brainnetome volumes of interest were calculated for both tracers, and the correlations of the z-scores were evaluated using Pearson\u2019s correlation coefficient. Lobar compartments, regions with significant neuronal injury (z-scores\u2009&lt;\u2009\u2009\u2212\u20093), and patients with different neurodegenerative disease entities (e.g., Alzheimer\u2019s disease or 4R-tauopathies) served for subgroup analysis. Additionally, we used partial regression to correlate regional perfusion alterations with clinical scores in cognition tests.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The z-scores of perfusion-weighted images of both tracers showed high correlations across the brain, especially in the frontal and parietal lobes, which were the brain regions with pronounced perfusion deficit in the patient group (\n                      <jats:italic>R<\/jats:italic>\n                      \u2009=\u20090.83\u2009\u00b1\u20090.08; range, 0.61\u20130.95). Z-scores of individual patients correlated well by region (\n                      <jats:italic>R<\/jats:italic>\n                      \u2009=\u20090.57\u2009\u00b1\u20090.15; range, 0.16\u20130.90), notably when significant perfusion deficits were present (\n                      <jats:italic>R<\/jats:italic>\n                      \u2009=\u20090.66\u2009\u00b1\u20090.15; range, 0.28\u20130.90).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      The early perfusion phases of [\n                      <jats:sup>18<\/jats:sup>\n                      F]PI-2620 tau- and [\n                      <jats:sup>18<\/jats:sup>\n                      F]flutemetamol-amyloid-PET are roughly equivalent indices of perfusion defect indicative of regional and lobar neuronal injury in patients with various neurodegenerative diseases. As such, either tracer may serve for two diagnostic channels by assessment of amyloid\/tau status and neuronal activity.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00259-022-06087-y","type":"journal-article","created":{"date-parts":[[2022,12,26]],"date-time":"2022-12-26T21:02:41Z","timestamp":1672088561000},"page":"1384-1394","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Assessment of perfusion deficit with early phases of [18F]PI-2620 tau-PET versus [18F]flutemetamol-amyloid-PET recordings"],"prefix":"10.1007","volume":"50","author":[{"given":"Friederike","family":"V\u00f6lter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonie","family":"Beyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Eckenweber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximilian","family":"Scheifele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ngoc","family":"Bui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianne","family":"Patt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henryk","family":"Barthel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina","family":"Katzdobler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Palleis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolai","family":"Franzmeier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Levin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Perneczky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boris-Stephan","family":"Rauchmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osama","family":"Sabri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jimin","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Cumming","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel","family":"Rominger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuangyu","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Bartenstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9247-2843","authenticated-orcid":false,"given":"Matthias","family":"Brendel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,12,27]]},"reference":[{"issue":"2","key":"6087_CR1","doi-asserted-by":"publisher","first-page":"e105","DOI":"10.1016\/S2468-2667(21)00249-8","volume":"7","author":"GDF Collaborators","year":"2022","unstructured":"Collaborators GDF. Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019. Lancet Public Health. 2022;7(2):e105\u201325.","journal-title":"Lancet Public Health"},{"issue":"3","key":"6087_CR2","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1038\/s41582-020-00454-9","volume":"17","author":"H Fillit","year":"2021","unstructured":"Fillit H, Green A. Aducanumab and the FDA \u2014 where are we now? Nat Rev Neurol. 2021;17(3):129\u201330.","journal-title":"Nat Rev Neurol"},{"issue":"4","key":"6087_CR3","first-page":"414","volume":"8","author":"SL Lowe","year":"2021","unstructured":"Lowe SL, et al. Donanemab (LY3002813) Phase 1b study in Alzheimer\u2019s disease: rapid and sustained reduction of brain amyloid measured by florbetapir F18 imaging. The Journal of Prevention of Alzheimer\u2019s Disease. 2021;8(4):414\u201324.","journal-title":"The Journal of Prevention of Alzheimer's Disease"},{"issue":"3","key":"6087_CR4","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/S1474-4422(13)70014-0","volume":"12","author":"R Dodel","year":"2013","unstructured":"Dodel R, et al. Intravenous immunoglobulin for treatment of mild-to-moderate Alzheimer\u2019s disease: a phase 2, randomised, double-blind, placebo-controlled, dose-finding trial. Lancet Neurol. 2013;12(3):233\u201343.","journal-title":"Lancet Neurol"},{"issue":"4","key":"6087_CR5","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.3233\/JAD-2010-100939","volume":"22","author":"S Tzimopoulou","year":"2010","unstructured":"Tzimopoulou S, et al. A multi-center randomized proof-of-concept clinical trial applying [18F]FDG-PET for evaluation of metabolic therapy with rosiglitazone XR in mild to moderate Alzheimer\u2019s disease. J Alzheimers Dis. 2010;22(4):1241\u201356.","journal-title":"J Alzheimers Dis"},{"key":"6087_CR6","doi-asserted-by":"crossref","unstructured":"Pleen JA-O. and R. Townley, Alzheimer's disease clinical trial update 2019\u20132021. (1432\u20131459 (Electronic)).","DOI":"10.1007\/s00415-021-10790-5"},{"key":"6087_CR7","unstructured":"Jack CR Jr. et al. A\/T\/N: an unbiased descriptive classification scheme for Alzheimer disease biomarkers. (1526\u2013632X (Electronic))."},{"issue":"4","key":"6087_CR8","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","volume":"14","author":"CR Jack Jr","year":"2018","unstructured":"Jack CR Jr, et al. NIA-AA research framework: toward a biological definition of Alzheimer\u2019s disease. Alzheimers Dement. 2018;14(4):535\u201362.","journal-title":"Alzheimers Dement"},{"issue":"12","key":"6087_CR9","doi-asserted-by":"publisher","first-page":"2911","DOI":"10.1007\/s00259-020-04788-w","volume":"47","author":"L Beyer","year":"2020","unstructured":"Beyer L, et al. Early-phase [18F]PI-2620 tau-PET imaging as a surrogate marker of neuronal injury. Eur J Nucl Med Mol Imaging. 2020;47(12):2911\u201322.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"3","key":"6087_CR10","doi-asserted-by":"publisher","first-page":"393","DOI":"10.2967\/jnumed.110.083683","volume":"52","author":"PT Meyer","year":"2011","unstructured":"Meyer PT, et al. Dual-biomarker imaging of regional cerebral amyloid load and neuronal activity in dementia with PET and 11C-labeled Pittsburgh compound B. J Nucl Med. 2011;52(3):393\u2013400.","journal-title":"J Nucl Med"},{"key":"6087_CR11","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.nicl.2016.10.005","volume":"14","author":"S Daerr","year":"2017","unstructured":"Daerr S, et al. Evaluation of early-phase [(18)F]-florbetaben PET acquisition in clinical routine cases. Neuroimage Clin. 2017;14:77\u201386.","journal-title":"Neuroimage Clin"},{"issue":"5","key":"6087_CR12","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1002\/ana.26465","volume":"92","author":"BS Rauchmann","year":"2022","unstructured":"Rauchmann BS, et al. Microglial activation and connectivity in Alzheimer disease and aging. Ann Neurol. 2022;92(5):768\u201381.","journal-title":"Ann Neurol"},{"issue":"9","key":"6087_CR13","doi-asserted-by":"publisher","first-page":"2104","DOI":"10.1002\/mds.28624","volume":"36","author":"C Palleis","year":"2021","unstructured":"Palleis C, et al. Cortical [(18) F]PI-2620 binding differentiates corticobasal syndrome subtypes. Mov Disord. 2021;36(9):2104\u201315.","journal-title":"Mov Disord"},{"issue":"5","key":"6087_CR14","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1212\/WNL.0b013e31827f0fd1","volume":"80","author":"MJ Armstrong","year":"2013","unstructured":"Armstrong MJ, et al. Criteria for the diagnosis of corticobasal degeneration. Neurology. 2013;80(5):496\u2013503.","journal-title":"Neurology"},{"issue":"6","key":"6087_CR15","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1002\/mds.26987","volume":"32","author":"GU Hoglinger","year":"2017","unstructured":"Hoglinger GU, et al. Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria. Mov Disord. 2017;32(6):853\u201364.","journal-title":"Mov Disord"},{"issue":"5","key":"6087_CR16","doi-asserted-by":"publisher","first-page":"375","DOI":"10.2165\/11533100-000000000-00000","volume":"24","author":"GD Rabinovici","year":"2010","unstructured":"Rabinovici GD, Miller BL. Frontotemporal lobar degeneration: epidemiology, pathophysiology, diagnosis and management. CNS Drugs. 2010;24(5):375\u201398.","journal-title":"CNS Drugs"},{"issue":"11","key":"6087_CR17","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1212\/WNL.0b013e31821103e6","volume":"76","author":"ML Gorno-Tempini","year":"2011","unstructured":"Gorno-Tempini ML, et al. Classification of primary progressive aphasia and its variants. Neurology. 2011;76(11):1006\u201314.","journal-title":"Neurology"},{"issue":"4","key":"6087_CR18","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1002\/mds.26498","volume":"31","author":"M Lawton","year":"2016","unstructured":"Lawton M, et al. Validation of conversion between mini\u2013mental state examination and Montreal cognitive assessment. Mov Disord. 2016;31(4):593\u20136.","journal-title":"Mov Disord"},{"issue":"7","key":"6087_CR19","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.2967\/jnumed.115.168732","volume":"57","author":"E Rodriguez-Vieitez","year":"2016","unstructured":"Rodriguez-Vieitez E, et al. Comparison of early-phase 11C-deuterium-l-deprenyl and 11C-Pittsburgh compound B PET for assessing brain perfusion in Alzheimer disease. J Nucl Med. 2016;57(7):1071\u20137.","journal-title":"J Nucl Med"},{"issue":"12","key":"6087_CR20","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.2967\/jnumed.120.257345","volume":"62","author":"S Peng","year":"2021","unstructured":"Peng S, et al. Dynamic 18F-FPCIT PET: quantification of Parkinson disease metabolic networks and nigrostriatal dopaminergic dysfunction in a single imaging session. J Nucl Med. 2021;62(12):1775.","journal-title":"J Nucl Med"},{"issue":"11","key":"6087_CR21","doi-asserted-by":"publisher","first-page":"1784","DOI":"10.1007\/s00259-012-2178-9","volume":"39","author":"A Snellman","year":"2012","unstructured":"Snellman A, et al. Pharmacokinetics of [18F]flutemetamol in wild-type rodents and its binding to beta amyloid deposits in a mouse model of Alzheimer\u2019s disease. Eur J Nucl Med Mol Imaging. 2012;39(11):1784\u201395.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"10","key":"6087_CR22","doi-asserted-by":"publisher","first-page":"2178","DOI":"10.1007\/s00259-019-04397-2","volume":"46","author":"H Kroth","year":"2019","unstructured":"Kroth H, et al. Discovery and preclinical characterization of [(18)F]PI-2620, a next-generation tau PET tracer for the assessment of tau pathology in Alzheimer\u2019s disease and other tauopathies. Eur J Nucl Med Mol Imaging. 2019;46(10):2178\u201389.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"11","key":"6087_CR23","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1001\/jamaneurol.2020.2526","volume":"77","author":"M Brendel","year":"2020","unstructured":"Brendel M, et al. Assessment of 18F-PI-2620 as a biomarker in progressive supranuclear palsy. JAMA Neurol. 2020;77(11):1408\u201319.","journal-title":"JAMA Neurol"},{"issue":"3","key":"6087_CR24","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.3233\/JAD-180522","volume":"66","author":"L Florek","year":"2018","unstructured":"Florek L, et al. Dual time-point [18F]florbetaben PET delivers dual biomarker information in mild cognitive impairment and Alzheimer\u2019s disease. J Alzheimers Dis. 2018;66(3):1105\u201316.","journal-title":"J Alzheimers Dis"},{"key":"6087_CR25","unstructured":"Katzdobler S et al. Additive value of [18F]PI-2620 perfusion imaging in four-repeat tauopathies. European Journal of Nuclear Medicine and Molecular Imaging, 2022."},{"issue":"7","key":"6087_CR26","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1007\/s12149-015-0986-2","volume":"29","author":"M Senda","year":"2015","unstructured":"Senda M, et al. The clinical safety, biodistribution and internal radiation dosimetry of flutemetamol ((1)(8)F) injection in healthy Japanese adult volunteers. Ann Nucl Med. 2015;29(7):627\u201335.","journal-title":"Ann Nucl Med"},{"key":"6087_CR27","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2021.661284","volume":"13","author":"J Schmitt","year":"2021","unstructured":"Schmitt J, et al. Dual-phase beta-amyloid PET captures neuronal injury and amyloidosis in corticobasal syndrome. Front Aging Neurosci. 2021;13: 661284.","journal-title":"Front Aging Neurosci"},{"issue":"8","key":"6087_CR28","doi-asserted-by":"publisher","first-page":"3508","DOI":"10.1093\/cercor\/bhw157","volume":"26","author":"L Fan","year":"2016","unstructured":"Fan L, et al. The human Brainnetome Atlas: a new brain atlas based on connectional architecture. Cereb Cortex. 2016;26(8):3508\u201326.","journal-title":"Cereb Cortex"},{"issue":"7","key":"6087_CR29","first-page":"1238","volume":"36","author":"S Minoshima","year":"1995","unstructured":"Minoshima S, et al. A diagnostic approach in Alzheimer\u2019s disease using three-dimensional stereotactic surface projections of fluorine-18-FDG PET. J Nucl Med. 1995;36(7):1238\u201348.","journal-title":"J Nucl Med"},{"key":"6087_CR30","doi-asserted-by":"crossref","unstructured":"Minoshima S et al. SNMMI procedure standard\/EANM practice guideline for amyloid PET imaging of the brain 1.0. J Nucl Med, 2016. 57(8): p. 1316\u201322.","DOI":"10.2967\/jnumed.116.174615"},{"issue":"7","key":"6087_CR31","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1007\/s00259-016-3393-6","volume":"43","author":"V Garibotto","year":"2016","unstructured":"Garibotto V, Morelli S, Pagani M. Dual-phase amyloid PET: hitting two birds with one stone. Eur J Nucl Med Mol Imaging. 2016;43(7):1300\u20133.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"9","key":"6087_CR32","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1007\/s00259-016-3353-1","volume":"43","author":"S Tiepolt","year":"2016","unstructured":"Tiepolt S, et al. Early [18F]florbetaben and [11C]PiB PET images are a surrogate biomarker of neuronal injury in Alzheimer\u2019s disease. Eur J Nucl Med Mol Imaging. 2016;43(9):1700\u20139.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"6087_CR33","doi-asserted-by":"publisher","first-page":"65","DOI":"10.3233\/JAD-180217","volume":"68","author":"S Tiepolt","year":"2019","unstructured":"Tiepolt S, et al. Early after administration [11C]PiB PET images correlate with cognitive dysfunction measured by the CERAD test battery. J Alzheimers Dis. 2019;68(1):65\u201376.","journal-title":"J Alzheimers Dis"},{"issue":"1","key":"6087_CR34","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1186\/s13550-020-00702-5","volume":"10","author":"J Toyohara","year":"2020","unstructured":"Toyohara J, et al. Synthesis and evaluation of N-isopropyl-p-[(11)C]methylamphetamine as a novel cerebral blood flow tracer for positron emission tomography. EJNMMI Res. 2020;10(1):115.","journal-title":"EJNMMI Res"},{"issue":"4","key":"6087_CR35","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1152\/japplphysiol.00276.2018","volume":"125","author":"OM Henriksen","year":"2018","unstructured":"Henriksen OM, et al. Interindividual and regional relationship between cerebral blood flow and glucose metabolism in the resting brain. J Appl Physiol. 2018;125(4):1080\u20139.","journal-title":"J Appl Physiol"},{"issue":"2","key":"6087_CR36","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/S1474-4422(12)70291-0","volume":"12","author":"CR Jack Jr","year":"2013","unstructured":"Jack CR Jr, et al. Tracking pathophysiological processes in Alzheimer\u2019s disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol. 2013;12(2):207\u201316.","journal-title":"Lancet Neurol"},{"issue":"Pt 5","key":"6087_CR37","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1093\/brain\/aww027","volume":"139","author":"R Ossenkoppele","year":"2016","unstructured":"Ossenkoppele R, et al. Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer\u2019s disease. Brain. 2016;139(Pt 5):1551\u201367.","journal-title":"Brain"},{"issue":"12","key":"6087_CR38","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1007\/s00234-007-0269-2","volume":"49","author":"G Karas","year":"2007","unstructured":"Karas G, et al. Precuneus atrophy in early-onset Alzheimer\u2019s disease: a morphometric structural MRI study. Neuroradiology. 2007;49(12):967\u201376.","journal-title":"Neuroradiology"},{"key":"6087_CR39","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1146\/annurev-bioeng-071114-040723","volume":"17","author":"JJ Vaquero","year":"2015","unstructured":"Vaquero JJ, Kinahan P. Positron emission tomography: current challenges and opportunities for technological advances in clinical and preclinical imaging systems. Annu Rev Biomed Eng. 2015;17:385\u2013414.","journal-title":"Annu Rev Biomed Eng"},{"key":"6087_CR40","doi-asserted-by":"crossref","unstructured":"Teuho J et al. Magnetic resonance-based attenuation correction and scatter correction in neurological positron emission tomography\/magnetic resonance imaging\u2014current status with emerging applications. Frontiers in Physics, 2020. 7.","DOI":"10.3389\/fphy.2019.00243"},{"issue":"6","key":"6087_CR41","doi-asserted-by":"publisher","first-page":"902","DOI":"10.2967\/jnumed.111.099606","volume":"53","author":"AB Newberg","year":"2012","unstructured":"Newberg AB, et al. Initial clinical comparison of 18F-florbetapir and 18F-FDG PET in patients with Alzheimer disease and controls. J Nucl Med. 2012;53(6):902\u20137.","journal-title":"J Nucl Med"},{"issue":"9","key":"6087_CR42","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.2967\/jnumed.112.116137","volume":"54","author":"S Shokouhi","year":"2013","unstructured":"Shokouhi S, et al. Longitudinal progression of cognitive decline correlates with changes in the spatial pattern of brain <sup>18<\/sup>F-FDG PET. J Nucl Med. 2013;54(9):1564\u20139.","journal-title":"J Nucl Med"},{"issue":"4","key":"6087_CR43","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1002\/syn.21630","volume":"67","author":"P Cumming","year":"2013","unstructured":"Cumming P, et al. Surrogate markers for cerebral blood flow correlate with [18F]-fallypride binding potential at dopamine D(2\/3) receptors in human striatum. Synapse. 2013;67(4):199\u2013203.","journal-title":"Synapse"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-022-06087-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-022-06087-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-022-06087-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,21]],"date-time":"2023-03-21T00:44:57Z","timestamp":1679359497000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-022-06087-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,27]]},"references-count":43,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["6087"],"URL":"https:\/\/doi.org\/10.1007\/s00259-022-06087-y","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-1995495\/v1","asserted-by":"object"}]},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,27]]},"assertion":[{"value":"24 August 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 December 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 December 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee (LMU Munich, application number 17\u2013569) and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from all patients.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"MB received speaker honoraria from GE healthcare, Roche, and LMI and is an advisor of LMI. OS received research support from LMI. HB received reader honoraria from LMI. JL reports speaker fees from Bayer Vital, Biogen, and Roche, consulting fees from Axon Neuroscience and Biogen, author fees from Thieme medical publishers and W. Kohlhammer GmbH medical publishers, non-financial support from Abbvie, and compensation for duty as part-time CMO from MODAG, all outside the submitted work. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}